MaxCyte: Allogene deal is validation for new CAR-T wave
MaxCyte’s (MXCT's) deal with clinical-stage industry leader Allogene Therapeutics (ALLO) is a clear endorsement of the features of its Flow Electroporation technology for enabling the production of the next generation of ‘off-the-shelf’ CAR-T therapies. Not only is this an impressive deal since ALLO is a landmark company in the field, but it also counts an array of scientific experts including ose who led the launch of Yescarta at Kite/Gilead, the second CAR-T therapy approved by the US Food & Drug Administration (FDA). Described by Allogene as the ‘industry standard’, MXCT’s Flow Electroporation has been chosen to improve yield and efficiency of its lead clinical programmes. This is critical to help fulfil the promise of such off-the-shelf treatments that can reach many more patients, much more quickly than first-gen CAR-T therapies, providing potentially curative outcomes in cancers as well as rare diseases.
Quick facts: MaxCyte Inc
Price: 125 GBX
Market Cap: £71.74 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE